KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Capital Expenditures (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Capital Expenditures for 16 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 86.25% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, down 34.84% year-over-year, with the annual reading at $7.0 million for FY2025, 34.84% down from the prior year.
  • Capital Expenditures for Q4 2025 was $1.4 million at Halozyme Therapeutics, down from $5.3 million in the prior quarter.
  • The five-year high for Capital Expenditures was $10.4 million in Q4 2024, with the low at -$5.8 million in Q3 2024.
  • Average Capital Expenditures over 5 years is $1.2 million, with a median of $349500.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures soared 19800.0% in 2022, then crashed 4659.84% in 2024.
  • Over 5 years, Capital Expenditures stood at -$30000.0 in 2021, then skyrocketed by 19800.0% to $5.9 million in 2022, then tumbled by 108.6% to -$508000.0 in 2023, then surged by 2142.52% to $10.4 million in 2024, then tumbled by 86.25% to $1.4 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1.4 million, $5.3 million, and -$207000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.